Trivium Point Advisory LLC Has $443,000 Stock Holdings in Danaher Corporation $DHR

Trivium Point Advisory LLC lifted its position in Danaher Corporation (NYSE:DHR) by 35.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,242 shares of the conglomerate’s stock after acquiring an additional 586 shares during the period. Trivium Point Advisory LLC’s holdings in Danaher were worth $443,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Eagle Wealth Strategies LLC raised its holdings in Danaher by 5.4% during the 2nd quarter. Eagle Wealth Strategies LLC now owns 1,099 shares of the conglomerate’s stock worth $217,000 after buying an additional 56 shares during the period. XML Financial LLC raised its holdings in Danaher by 7.9% during the 2nd quarter. XML Financial LLC now owns 6,884 shares of the conglomerate’s stock worth $1,360,000 after buying an additional 504 shares during the period. G&S Capital LLC raised its holdings in Danaher by 2.3% during the 2nd quarter. G&S Capital LLC now owns 10,132 shares of the conglomerate’s stock worth $2,002,000 after buying an additional 227 shares during the period. Capital Investment Advisors LLC raised its holdings in Danaher by 1.2% during the 2nd quarter. Capital Investment Advisors LLC now owns 7,352 shares of the conglomerate’s stock worth $1,452,000 after buying an additional 85 shares during the period. Finally, Kavar Capital Partners Group LLC raised its holdings in Danaher by 0.8% during the 2nd quarter. Kavar Capital Partners Group LLC now owns 48,148 shares of the conglomerate’s stock worth $9,511,000 after buying an additional 391 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

NYSE:DHR opened at $198.05 on Wednesday. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.41. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The firm has a fifty day simple moving average of $199.55 and a 200 day simple moving average of $197.31. The stock has a market capitalization of $141.82 billion, a PE ratio of 42.14, a P/E/G ratio of 2.65 and a beta of 0.75.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. During the same period last year, the business earned $1.72 earnings per share. The firm’s revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s payout ratio is 27.23%.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

DHR has been the topic of several research analyst reports. UBS Group dropped their target price on shares of Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, July 23rd. Barclays reiterated an “overweight” rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Evercore ISI lowered their price objective on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Robert W. Baird lifted their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a report on Friday, July 18th. Finally, Wells Fargo & Company lowered their price objective on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $245.91.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.